An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.
Study Type
OBSERVATIONAL
Enrollment
500
Percentage of Participants Achieving Best Overall Response Rate (ORR)
ORR is defined as the percentage of participants achieving partial response (PR) and complete response with incomplete regeneration of bone marrow (CRi) and complete response (CR) according to physician's assessment to therapy with venetoclax.
Time frame: Up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Universitaetsklinikum St. Poelten /ID# 221152
Sankt Pölten, Lower Austria, Austria
COMPLETEDMedizinische Universitaet Graz /ID# 221155
Graz, Styria, Austria
COMPLETEDLandeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 221153
Salzburg, Austria
ACTIVE_NOT_RECRUITINGHanusch Krankenhaus /ID# 221151
Vienna, Austria
COMPLETEDStauferklinikum Schwaebisch Gmuend /ID# 201518
Mutlangen, Baden-Wurttemberg, Germany
COMPLETEDOnkologische Praxis /ID# 201545
Stuttgart, Baden-Wurttemberg, Germany
COMPLETEDSchwarzwald-Baar-Klinikum /ID# 208176
Villingen-Schwenningen, Baden-Wurttemberg, Germany
COMPLETEDMVZ am Klinikum Aschaffenburg Onkologie /ID# 201548
Aschaffenburg, Bavaria, Germany
COMPLETEDStudienzentrum Aschaffenburg /ID# 204125
Aschaffenburg, Bavaria, Germany
COMPLETEDGemeinschaftspraxis Dr. Heinrich und Prof. Bangerter /ID# 200950
Augsburg, Bavaria, Germany
COMPLETED...and 62 more locations